Skip to main content
. 2021 Sep 17;65(10):e01155-21. doi: 10.1128/AAC.01155-21

FIG 4.

FIG 4

SARS-CoV-2 inhibitory activity replicate experiments. (A and B) Antiviral dose-response curves for three remdesivir analogs, remdesivir (GS-5734), and remdesivir nucleoside (GS-441524) against SARS-CoV-2 infection in multiple cell types. SARS-CoV-2 relative viral RNA reduction (A) and percent inhibition (B) in the indicated cell types. Cells were pretreated with the indicated dose of the indicated drug for 30 min and then infected with SARS-CoV-2 isolate USA-WA1/2020 for 48 h. The relative SARS-CoV-2 spike RNA expression was determined by qRT-PCR. (C) Cytotoxicity in the indicated cells incubated in the presence of the indicated drug at the indicated concentration for 48 h, after which, cell viability was measured by the CellTiter-Glo assay. (A to C) Each antiviral and cytotoxicity dose-response data point indicates the average from 3 independent experiments performed in duplicates, except as indicated in Table 1. Error bars represent the standard errors of the means (SEMs).